Ursula A. Matulonis, MD

Articles

Dr. Matulonis on CPS as a Potential Biomarker in Advanced Recurrent Ovarian Cancer

August 13th 2020

Ursula A. Matulonis, MD, discusses the potential role of combined positive score as a biomarker in advanced recurrent ovarian cancer.

Dr. Matulonis on the Current Treatment Landscape in Ovarian Cancer

July 2nd 2020

Ursula A. Matulonis, MD, discusses the current treatment landscape in ovarian cancer.

Dr. Matulonis on Final Data From KEYNOTE-100 in Recurrent Ovarian Cancer

June 11th 2020

Ursula A. Matulonis, MD, discusses final data from the phase 2 KEYNOTE-100 trial with pembrolizumab (Keytruda) in advanced recurrent ovarian cancer.

Dr. Matulonis on Final Data From KEYNOTE-100 in Recurrent Ovarian Cancer

June 10th 2020

Ursula A. Matulonis, MD, discusses final data from the phase 2 KEYNOTE-100 trial with pembrolizumab (Keytruda) in advanced recurrent ovarian cancer.

Dr. Matulonis on Individualized Dosing of Niraparib in Ovarian Cancer

March 26th 2019

Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses individualized dosing of niraparib in the treatment of patients with ovarian cancer.

Dr. Matulonis on the Use of Immunotherapy in Recurrent Ovarian Cancer

January 11th 2019

Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the use of immunotherapy in patients with recurrent ovarian cancer.

Dr. Matulonis Discusses QoL Data from GOG-258 in Endometrial Cancer

August 17th 2018

Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the quality-of-life outcomes from the GOG-258 trial in patients with endometrial cancer.

Dr. Matulonis Discusses Rationale of QUADRA Trial

July 24th 2018

Ursula A. Matulonis, MD, chief, Division of Gynecological Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the rationale behind the QUADRA trial for patients with relapsed ovarian cancer.

Dr. Matulonis Discusses Niraparib/Pembrolizumab Combo in Platinum-Resistant Ovarian Cancer

March 26th 2018

Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the TOPACIO trial, which explored preliminary activity and safety of niraparib (Zejula) and pembrolizumab (Keytruda) in patients with platinum-resistant ovarian cancer, during the 2018 Society of Gynecologic Oncology Annual Meeting.

Dr. Matulonis on Toxicities With PARP Inhibitors in Ovarian Cancer

May 23rd 2017

Ursula A. Matulonis, MD, professor of Medicine, Harvard Medical School, medical director of Gynecologic Oncology, Dana-Farber Cancer Institute, discusses toxicities associated with PARP inhibitors in ovarian cancer.

x